Depressive Disorder News and Research

RSS

New mothers often not asked about depression

The majority of doctors in North Carolina do not probe for signs of postpartum depression in new mothers, according to a survey conducted by researchers at the University of North Carolina at Chapel Hill.

1 Jun 2007

Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder

In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.

24 May 2007

FDA wants new warnings on antidepressant medications

The U.S. Food and Drug Administration (FDA) has proposed that makers of all antidepressant medications update the existing black box warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment (generally the first one to two months).

4 May 2007

FDA - all antidepressants need new warning labels

The Food and Drug Administration (FDA) in the United States wants the manufacturers of antidepressant medications to change the labels on their products.

3 May 2007

Childhood-onset bipolar disorder is more common than believed

In bipolar disorder, also called manic-depressive disorder, a person experiences mood changes that fluctuate between periods of abnormally high energy and extreme depression.

2 May 2007

Pregnant U.S. women commonly smoke

While pregnancy may be considered an effective motivator for smoking cessation, results of a new study by researchers at the Mailman School of Public Health indicate that pregnant U.S. women commonly smoke, placing themselves and their unborn children at risk for health and developmental complications.

25 Apr 2007

Benefits of antidepressants for children far outweigh the risks

Researchers in the United States maintain that a review of research shows that the benefits of antidepressants for children and teens during the first few months of treatment far outweigh the risk of suicide.

22 Apr 2007

Review of all major studies involving anti-depressants in children

Today, the Journal of the American Medical Association (JAMA) published a review of all major studies involving anti-depressants in children and adolescents by a team of researchers from Western Psychiatric Institute in Pittsburgh.

18 Apr 2007

Risks and benefits of antidepressant treatment for children with depression

According to a new study, conducted by the Center for Innovation in Pediatric Practice (CIPP) at Columbus Children's Hospital and published in the April 18 issue of The Journal of the American Medical Association (JAMA), there is more information for parents about the risks and benefits of antidepressant treatment for children with depression and anxiety disorders.

18 Apr 2007

Benefits of antidepressants for children and teens with depression or anxiety disorders may outweigh risks

A review of previous studies indicates that the benefits of antidepressants for children and teens with depression or anxiety disorders may outweigh their risks, and that the increased risk for suicidal thoughts and attempts from using these medications is not statistically significant, according to an article in the April 18 issue of JAMA.

18 Apr 2007

Antidepressants safe for children and adolescents - black box warnings questioned

Antidepressants are safe and effective for treating anxiety, obsessive compulsive disorder (OCD) and major depressive disorder in children and adolescents, according to a meta-analysis of 27 major studies.

18 Apr 2007

Internet can help people identify depression

This is the conclusion of a study published in BMC Psychiatry, which demonstrates that a Chinese online tool for assessing depression is both accurate and reproducible, and may offer a way to identify the growing number of people suffering from depression.

11 Apr 2007

FDA approves antidepressant Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved the antidepressant Cymbalta (duloxetine HCl) for the treatment of generalized anxiety disorder (GAD), a condition that affects more than 6.5 million American adults in a given year.

26 Feb 2007

CeNeRx BioPharma starts human trials of RIMA antidepressant

CeNeRx BioPharma, Inc. has announced the initiation of human clinical trials of Tyrima, CeNeRx's new drug candidate with a triple mechanism of action for the treatment of depression and anxiety.

30 Jan 2007

Link between insomnia and depression in children

According to a study published in the journal SLEEP, sleep-disturbed children are more severely depressed and have more depressive symptoms and comorbid anxiety disorders compared with children without sleep disturbance.

2 Jan 2007

FDA announces tentative approval of generic Zoloft

Lupin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Tablets, 25mg, 50mg and 100mg.

2 Jan 2007

SSRIs associated with severe violence in a small number of individuals

Use of one class of antidepressant drugs, the SSRIs (selective serotonin reuptake inhibitors), may be associated with severe violence in a small number of individuals say the authors of paper published in PLoS Medicine.

12 Sep 2006

Bipolar disorder costs twice as much in lost productivity as major depressive disorder

Bipolar disorder costs twice as much in lost productivity as major depressive disorder, a study funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) has found. Each U.S. worker with bipolar disorder averaged 65.5 lost workdays in a year, compared to 27.2 for major depression.

4 Sep 2006

FDA approves generic version of Effexor (venlafaxine)

The U.S. Food and Drug Administration has approved the first generic version of Effexor (venlafaxine), an important step in the agency's effort to increase the availability of lower-cost generic medications.

9 Aug 2006